HPLC-MS Study on Lipidomics for Coronary Artery Disease Patients' Serum and Its Significance in Clinical Medicine

HPLC-MS was established to study the lipidomics of serum samples for the patients with chronic complete coronary occlusion (CTO) at the different stages of disease. Patients' serum of suspected CTO, CTO, and CTO after 24 h and 72 h of percutaneous coronary intervention (PCI) surgery were collected respectively in the test. The lipid in samples was extracted with chloroform and ethyl acetate-isooctane with volume ratio of 25:75, respectively. After centrifugation, the supernatant was taken for Shotgun method (MS) and multiple reaction monitoring (MRM) method (HPLC-MS). The supernatant sample was injected directly to electrospray (ESI) mass spectrometry for a broad-lipidomics analysis and identification by Shotgun method. The MS data was indexed and analyzed by software Analyst 1.6, and the lipid molecules were confirmed by the bioinformatics tool “Lipid MS Predict”. A total of 1 504 lipid molecules were identified, and among them, 631 lipid molecules with clinical significance were confirmed by using the MRM method. Through bioinformatics analysis, 9 lipid molecules with significance in CTO diagnosis at early stage were ascertained as the biomarker, including cholesterol ester (CE) 16:1 and lysophosphatidylethanolamine (LPE) 18:1. Feedback from the clinical return visit as well as research data confirmed that the postoperative risk prognosis of CTO patients was correlated positively with the increase of content of 3 lipid molecules including phosphatidic acid, phosphatidylcholine, and cholesterol ester. The lipid biomarkers found in the study can be applied to the clinical diagnosis of coronary heart disease at early stage and assessment of the risk after surgery, with definite significance and clear clinical medical value.